Clinical trials: Lymphoma, Follicular
Lymphoma
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
The purpose of this study is to assess the clinical benefit of Nivolumab, as measured by independent radiologic review committee (IRRC)-assessed objective response rate (ORR) in subjects with FL lymphoma who have failed therapy…
- Trial name
- NCT02038946
- Testing
- Nivolumab
- Where
- 45 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Bristol-Myers Squibb
Moderate or Severe Submental Fullness
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
- Trial name
- NCT01546142
- Testing
- Deoxycholic acid injection
- Where
- 35 sites in United States, Canada
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
CLL/SLL, NHL
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-760 in patients with previously treated CLL/SLL or NHL
- Conditions
- CLL/SLL, NHL, MCL, MZL
- Trial name
- NCT05176691
- Testing
- HMPL-760
- Where
- 36 sites in United States, Australia and 5 more
- Sponsor
- Hutchmed
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim
This is an open-label study of safety, tolerability, pharmacokinetics and pharmacodynamics of Auriхim multiple doses in patients with recurrent/ refractory В-cell, CD20-positive non-Hodgkin lymphoma of low tumor grade or with…
- Trial name
- NCT03057418
- Testing
- Aurixim
- Where
- 3 sites in Russia
- Volunteers
- 7 people
- Sponsor
- Biointegrator LLC
Anxiety, Efficacy
Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety
To evaluate the efficacy and tolerability of the combination use of Passiflora incarnata L, Crataegus oxyacantha and Salix alba L in mild and moderate anxiety. Clinical study phase III, multicenter, prospective, open.
- Conditions
- Anxiety, Efficacy, Tolerability
- Trial name
- E01ATCAL0308 (NCT00944268)
- Testing
- Passiflora, Crataegus e Salix
- Where
- Brazil
- Volunteers
- 124 people
- Sponsor
- Ativus Farmaceutica Ltda
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
This study is testing the safety and tolerability of BGB-21447 monotherapy in participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Conditions
- Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT05828589
- Testing
- BGB-21447
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 51 people
- Sponsor
- BeOne Medicines
Lymphoma, Follicular
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
The purpose of this study is to evaluate the efficacy (effectiveness) and tolerability (how well a participant can stand a particular medicine or treatment; ability to be used) of bortezomib in combination with rituximab standard…
- Trial name
- NCT01902862
- Testing
- Bortezomib, Rituximab
- Where
- 3 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Janssen-Cilag G.m.b.H
Follicular Lymphoma (FL)
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma.
- Trial name
- OLYMPIA-2 (NCT06097364)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 145 sites in United States, Australia and 15 more
- Volunteers
- 733 people
- Sponsor
- Regeneron Pharmaceuticals
Follicular Lymphoma
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available…
- Trial name
- RELEVANCE (NCT01476787)
- Testing
- Rituximab, Lenalidomide, Rituximab-CHOP
- Where
- 36 sites in United States, Japan
- Volunteers
- 1,030 people
- Sponsor
- Celgene
Non-Hodgkin's Lymphoma
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
This is a open-label, multicenter, non-randomized, study to evaluate the safety, efficacy, and pharmacokinetics of idasanutlin in combination with obinutuzumab in participants with R/R FL and rituximab in combination with…
- Trial name
- NCT02624986
- Testing
- Idasanutlin, Obinutuzumab, Rituximab
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Asthma
Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years
A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FLUTIFORM® pMDI (2 puffs bid) vs Seretide® pMDI (2 puffs bid) in subjects aged ≥12 years with moderate to…
- Trial name
- NCT03387241
- Testing
- Fluticasone/ Formoterol, fluticasone/ salmeterol
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Moderate or Severe Submental Fullness
Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area
To determine the dosing interval, optimal dose, evaluate safety, and efficacy of AYP-101 S.C injection for the reduction of Submental Fat (SMF).
- Trial name
- NCT05266729
- Testing
- Polyene Phosphatidylcholine
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AMIpharm Co., Ltd.
Pain
Pharmacokinetics & Safety of Diclofenac Potassium Oral Solution in Ped. Subjects (2-12 Yrs) With Mild-Mod. Acute Pain
As part of the Pediatric Research Equity Act (PREA) commitment, the objectives of the study are to characterize the pharmacokinetic (PK) profile and to determine the safety and tolerability of diclofenac potassium oral solution…
- Trial name
- NCT02287350
- Testing
- diclofenac potassium oral solution
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Depomed
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R) B-cell hematological malignancies and failure of…
- Conditions
- Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory, Follicular Lymphoma ( FL), Primary Mediastinal Large B-Cell Lymphoma-Refractory
- Trial name
- CD20/19 CAR T (NCT06703892)
- Testing
- GF-CART01
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- GenomeFrontier Therapeutics TW Co., Ltd.
Mild or Moderate Surgical Bleeding
A Study of Fibrocaps™ in Surgical Bleeding
The purpose of this study is to confirm the superiority of Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone, for achieving hemostasis.
- Trial name
- FINISH-3 (NCT01527357)
- Testing
- Fibrocaps, Gelatin sponge
- Where
- 48 sites in United States, Belgium and 2 more
- Volunteers
- 721 people
- Sponsor
- Mallinckrodt
Malaria
Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.
The objective of the study is to assess the efficacy and safety of SAR97276A in severe malaria in pediatric patients. Before treating pediatric patients with severe malaria, the efficacy and safety of SAR97276A will be first…
- Trial name
- NCT00739206
- Testing
- SAR97276A
- Where
- 4 sites in Benin, Burkina Faso and 2 more
- Volunteers
- 113 people
- Sponsor
- Sanofi
Lymphoma, Follicular
Autologous Vaccine for Follicular Lymphoma
This phase I study will evaluate the safety and tolerability of an autologous idiotype vaccine manufactured by magnICON technology for patients with relapsed follicular lymphoma who are in complete or partial remission following…
- Trial name
- NCT01022255
- Testing
- Autologous FL vaccine
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Icon Genetics GmbH
Follicular Lymphoma, Chronic Lymphocytic Leukemia
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
This study will evaluate the safety and tolerability of GS-9901 monotherapy in adults with follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL).
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT02258555
- Testing
- GS-9901
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gilead Sciences
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
This is a Phase I, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated…
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT04018248
- Testing
- BR101801 (Phase Ia), BR101801 (Phase Ib)
- Where
- 9 sites in United States, South Korea
- Volunteers
- 26 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Follicular Non-Hodgkin's Lymphoma Refractory
Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma
The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).
- Trial name
- ZEUS (NCT03568929)
- Testing
- Idelalisib
- Where
- 88 sites in Belgium, France and 8 more
- Volunteers
- 257 people
- Sponsor
- Gilead Sciences